Pancreatic Cancer

The study reveals two druggable targets that hold promise as treatments that stop pancreatic cancer’s spread.  

A triple combination of an investigational drug that enables immune cells to infiltrate tumors, an immunotherapy drug and chemotherapy showed promising responses in patients with the most common type of metastatic pancreatic cancer

Pancreatic cancer is expected to become the second-deadliest cancer in the United States by 2030. Many researchers believe that the rise in obesity is a key factor in this increase

Waiting in the starting blocks, sprinters’ muscles are about to need to produce a lot of energy. And quickly. For short bursts of energy like this, the body can’t rely on its usual methods of production.

The targeted drug palbociclib may boost the effectiveness of chemotherapy in pancreatic cancer if the two treatments are given in the right sequence

Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to live for at least five years after being diagnosed

how two subtypes of pancreatic cancer respond to treatments differently. Importantly, they found that one subtype of the disease showed poor responses to common therapies, and also had worse survival rates

UBC scientists have demonstrated for the first time a causal link between high insulin levels and pancreatic cancer.